Perbak Capital Partners LLP Raises Stock Position in Waters Corporation $WAT

Perbak Capital Partners LLP raised its holdings in shares of Waters Corporation (NYSE:WAT) by 62.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,928 shares of the medical instruments supplier’s stock after acquiring an additional 3,829 shares during the quarter. Waters makes up about 0.5% of Perbak Capital Partners LLP’s investment portfolio, making the stock its 21st biggest position. Perbak Capital Partners LLP’s holdings in Waters were worth $2,977,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in WAT. Root Financial Partners LLC bought a new stake in Waters during the 3rd quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd bought a new position in Waters in the 3rd quarter worth approximately $26,000. Hantz Financial Services Inc. grew its holdings in Waters by 115.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 112 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 60 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in Waters during the 2nd quarter valued at approximately $53,000. Finally, MUFG Securities EMEA plc bought a new stake in shares of Waters during the second quarter valued at approximately $61,000. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Waters Trading Up 1.1%

Shares of WAT opened at $286.42 on Friday. The stock has a market capitalization of $28.10 billion, a PE ratio of 26.59, a P/E/G ratio of 1.95 and a beta of 1.20. The company’s fifty day moving average is $352.67 and its 200 day moving average is $350.81. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.27 and a current ratio of 1.73. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15.

Waters (NYSE:WAT) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $4.53 EPS for the quarter, beating the consensus estimate of $4.50 by $0.03. Waters had a net margin of 20.30% and a return on equity of 34.79%. The business had revenue of $932.36 million during the quarter, compared to analyst estimates of $928.17 million. During the same quarter last year, the business earned $4.10 earnings per share. Waters’s quarterly revenue was up 6.9% compared to the same quarter last year. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Sell-side analysts expect that Waters Corporation will post 12.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on WAT shares. Wall Street Zen lowered shares of Waters from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Guggenheim reiterated a “buy” rating and issued a $440.00 price target on shares of Waters in a report on Tuesday, February 10th. Bank of America decreased their price target on shares of Waters from $410.00 to $350.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Wolfe Research raised shares of Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 price objective for the company in a report on Wednesday, December 10th. Finally, Citigroup initiated coverage on Waters in a research report on Tuesday, February 10th. They set a “buy” rating and a $425.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $393.84.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.